FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094599067> ?p ?o ?g. }

• W3094599067 endingPage "e27" @default.
• W3094599067 startingPage "e27" @default.
• W3094599067 abstract "Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer (BC), with high propensity for distant metastases. Previous data has suggested that aspirin use may be associated with improved risk of distant metastases in aggressive breast cancer, but there are no reported studies of potential benefit of aspirin use in IBC patients. Our goal was to determine whether there is an association of aspirin use with improvement in outcomes for patients with IBC. Patients with non-metastatic IBC treated from 2000-2017 at two institutions were reviewed (IRB protocol STU- 052012-019). Clinicopathologic data, including evidence of aspirin use in remission period (beginning within 2 years of diagnosis and lasting for a minimum of 60 days), was collected and analyzed. Overall survival (OS), disease free survival (DFS), and distant metastases free survival (DMFS) were obtained using Kaplan Meier analysis. Univariate and multivariate logistic regression models were constructed to identify significant factors. 59 patients meeting criteria for analysis were available for review, of which 14 aspirin users were identified. The aspirin and non-aspirin groups did not show any significant distribution differences in patient characteristics (e.g. ER/PR status, pathologic tumor (pT) stage, pathologic nodal (pN) stage, LVI, endocrine therapy use, chemotherapy use, triple negative status). Aspirin users demonstrated increased OS (p = .03) and DMFS (p = .02), with 4-year OS and DMFS of 92% (p = .01) and 85% (p = .01) compared to 56% and 43% respectively for non-aspirin users. On univariate analysis, pT stage, pN stage, and aspirin use, were significantly correlated (p<.05) with OS and DFS. On multivariate analysis, aspirin use (HR = .11, CI 0.01- 0.8) and lymph node stage (HR = 5.9, CI 1.4-25.9) remained significant for OS and DFS (aspirin use (HR = 0.13, CI 0.03-0.56) and lymph node stage (HR = 5.6, CI 1.9-16.4). Aspirin use initiated during remission period was associated with significantly improved OS and DMFS in IBC patients. These hypotheses-generating results suggests that aspirin use may provide survival benefit for IBC patients. Prospective clinical trial(s) of augmented ASA use in patients with high risk IBC in remission should be considered for development." @default.
• W3094599067 created "2020-10-29" @default.
• W3094599067 creator A5000962617 @default.
• W3094599067 creator A5025550989 @default.
• W3094599067 creator A5027297522 @default.
• W3094599067 creator A5030604633 @default.
• W3094599067 creator A5030894591 @default.
• W3094599067 creator A5050391090 @default.
• W3094599067 creator A5056023437 @default.
• W3094599067 date "2020-11-01" @default.
• W3094599067 modified "2023-09-26" @default.
• W3094599067 title "Aspirin Use is Associated with Improvement in Overall Survival and Recurrence Free Survival in Inflammatory Breast Cancer Patients" @default.
• W3094599067 doi "https://doi.org/10.1016/j.ijrobp.2020.07.1048" @default.
• W3094599067 hasPublicationYear "2020" @default.
• W3094599067 type Work @default.
• W3094599067 sameAs 3094599067 @default.
• W3094599067 citedByCount "1" @default.
• W3094599067 countsByYear W30945990672023 @default.
• W3094599067 crossrefType "journal-article" @default.
• W3094599067 hasAuthorship W3094599067A5000962617 @default.
• W3094599067 hasAuthorship W3094599067A5025550989 @default.
• W3094599067 hasAuthorship W3094599067A5027297522 @default.
• W3094599067 hasAuthorship W3094599067A5030604633 @default.
• W3094599067 hasAuthorship W3094599067A5030894591 @default.
• W3094599067 hasAuthorship W3094599067A5050391090 @default.
• W3094599067 hasAuthorship W3094599067A5056023437 @default.
• W3094599067 hasBestOaLocation W30945990671 @default.
• W3094599067 hasConcept C121608353 @default.
• W3094599067 hasConcept C126322002 @default.
• W3094599067 hasConcept C141071460 @default.
• W3094599067 hasConcept C143998085 @default.
• W3094599067 hasConcept C144301174 @default.
• W3094599067 hasConcept C146357865 @default.
• W3094599067 hasConcept C151730666 @default.
• W3094599067 hasConcept C2777628954 @default.
• W3094599067 hasConcept C2780839634 @default.
• W3094599067 hasConcept C38180746 @default.
• W3094599067 hasConcept C530470458 @default.
• W3094599067 hasConcept C71924100 @default.
• W3094599067 hasConcept C86803240 @default.
• W3094599067 hasConceptScore W3094599067C121608353 @default.
• W3094599067 hasConceptScore W3094599067C126322002 @default.
• W3094599067 hasConceptScore W3094599067C141071460 @default.
• W3094599067 hasConceptScore W3094599067C143998085 @default.
• W3094599067 hasConceptScore W3094599067C144301174 @default.
• W3094599067 hasConceptScore W3094599067C146357865 @default.
• W3094599067 hasConceptScore W3094599067C151730666 @default.
• W3094599067 hasConceptScore W3094599067C2777628954 @default.
• W3094599067 hasConceptScore W3094599067C2780839634 @default.
• W3094599067 hasConceptScore W3094599067C38180746 @default.
• W3094599067 hasConceptScore W3094599067C530470458 @default.
• W3094599067 hasConceptScore W3094599067C71924100 @default.
• W3094599067 hasConceptScore W3094599067C86803240 @default.
• W3094599067 hasIssue "3" @default.
• W3094599067 hasLocation W30945990671 @default.
• W3094599067 hasOpenAccess W3094599067 @default.
• W3094599067 hasPrimaryLocation W30945990671 @default.
• W3094599067 hasRelatedWork W1970545001 @default.
• W3094599067 hasRelatedWork W2018149194 @default.
• W3094599067 hasRelatedWork W2134757960 @default.
• W3094599067 hasRelatedWork W2325786172 @default.
• W3094599067 hasRelatedWork W2411442805 @default.
• W3094599067 hasRelatedWork W2415741046 @default.
• W3094599067 hasRelatedWork W2563193111 @default.
• W3094599067 hasRelatedWork W2980359604 @default.
• W3094599067 hasRelatedWork W3136323861 @default.
• W3094599067 hasRelatedWork W377899687 @default.
• W3094599067 hasVolume "108" @default.
• W3094599067 isParatext "false" @default.
• W3094599067 isRetracted "false" @default.
• W3094599067 magId "3094599067" @default.
• W3094599067 workType "article" @default.